S
BMRN icon

Surevest’s BioMarin Pharmaceuticals BMRN Stock Holding History

Surevest’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$26K Hold
308
– – 0.01% 222
2022
Q2 		$26K Hold
308
– – 0.01% 240
2022
Q1 		$24K Hold
308
– – 0.01% 225
2021
Q4 		$27K Buy
+308
New +$25.4K 0.01% 218

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Surevest's BMRN Position: Q3 2022 in Review

Surevest held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2022 at 308 shares worth $26K. The position accounts for 0.01% of the portfolio, ranked #222.

Surevest first reported a position in BMRN in Q4 2021 and has held it in 4 quarters since. The position peaked at $27K in Q4 2021. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • Surevest held 308 shares of BioMarin Pharmaceuticals worth $26K as of Q3 2022.
  • Surevest left its BioMarin Pharmaceuticals share count unchanged in Q3 2022.
  • BioMarin Pharmaceuticals made up 0.01% of Surevest's portfolio in Q3 2022, its #222 holding.
  • Surevest first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • Surevest's BioMarin Pharmaceuticals position peaked at $27K in Q4 2021.
  • 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Surevest's 13F filing for Q3 2022, filed 14 Nov 2022.